Poirier Valerie J, Thamm Douglas H, Kurzman Ilene D, Jeglum K Ann, Chun Ruthanne, Obradovich Joyce E, O'Brien Maura, Fred Rogers M, Phillips Brenda S, Vail David M
Department of Medical Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA.
J Vet Intern Med. 2002 Nov-Dec;16(6):726-31.
The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome-encapsulated doxorubicin (LED) and doxorubicin (DOX) in the treatment of feline vaccine-associated sarcoma (VAS). Cats were divided according to their disease status into a microscopic arm (no evidence of gross disease) and a macroscopic arm (evidence of gross disease). Each arm was randomized to receive either LED (1-1.5 mg/kg i.v. q3 weeks) or DOX (1 mg/kg i.v. q3 weeks). Thirty-three cats were entered in the macroscopic arm of the study with an overall response rate of 39% (5 complete response and 8 partial response) and a median time to progression of 84 days. Response rates were not different between LED and DOX. Seventy-five cats were entered into the microscopic arm. When compared to a similar historical control population treated with surgery alone, the cats receiving chemotherapy had a prolonged median disease-free interval (388 days versus 93 days). No difference in efficacy was detected between LED and DOX. LED at 1.5 mg/kg induced delayed nephrotoxicosis in 23%, necessitating a decrease in the recommended dosage to 1 mg/kg, and cutaneous toxicosis in 21.7% of treated cats. This study showed that both DOX and LED are efficacious in the treatment of VAS and should be considered in the treatment of this tumor.
这项随机、多中心研究的目的是评估脂质体包裹阿霉素（LED）和阿霉素（DOX）治疗猫疫苗相关肉瘤（VAS）的毒性和疗效。猫根据疾病状态分为微观组（无肉眼可见疾病证据）和宏观组（有肉眼可见疾病证据）。每组随机接受LED（1 - 1.5mg/kg静脉注射，每3周一次）或DOX（1mg/kg静脉注射，每3周一次）。33只猫进入研究的宏观组，总缓解率为39%（5例完全缓解和8例部分缓解），中位疾病进展时间为84天。LED和DOX之间的缓解率无差异。75只猫进入微观组进行研究。与仅接受手术治疗的类似历史对照群体相比，接受化疗的猫中位无病生存期延长（388天对93天）。LED和DOX之间未检测到疗效差异。1.5mg/kg的LED在23%的猫中引起延迟性肾毒性，因此推荐剂量降至1mg/kg，21.7%接受治疗的猫出现皮肤毒性。这项研究表明，DOX和LED在治疗VAS方面均有效，在治疗这种肿瘤时应予以考虑。
